VIP 5mg
Vasoactive Intestinal Peptide for Immune and Pulmonary Research
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide with broad anti-inflammatory, bronchodilatory, immunomodulatory, and neuroprotective properties. Studied for autoimmune disease, COPD, pulmonary hypertension, and autism spectrum disorder.
Vasoactive Intestinal Peptide for Immune and Pulmonary Research
VIP activates VPAC1 and VPAC2 receptors to stimulate cAMP, producing smooth muscle relaxation, Th2/Treg polarization, and inhibition of pro-inflammatory cytokines. Its anti-inflammatory and immunomodulatory properties make it relevant for a broad range of autoimmune and inflammatory diseases.
As one of the most studied compounds in the recovery & healing research space, VIP has attracted sustained scientific interest across Pulmonary hypertension research, Autoimmune disease studies, Neuroinflammation research. Peer-reviewed evidence indicates that phase 2 trials for pulmonary arterial hypertension, which has positioned VIP as a reference standard for researchers exploring pulmonary hypertension research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
VIP Documented Benefits: 4 Documented Mechanisms
Anti-Inflammatory
Inhibits TNF-α, IL-6, and IL-12 while promoting IL-10 and regulatory T-cell polarization.
Bronchodilation
Relaxes bronchial smooth muscle; studied for asthma and COPD treatment.
Pulmonary Hypertension
In clinical trials for PAH; reduces pulmonary vascular resistance via cAMP/PKA.
Neuroprotection
Protects neurons and supports neurogenesis via BDNF and NGF upregulation.
How VIP Works: Molecular Mechanism & Pathway
VPAC1/VPAC2 receptor agonist activating adenylyl cyclase/cAMP/PKA to relax smooth muscle, polarize Th2/Treg immunity, and suppress pro-inflammatory signaling.
The 4 primary research pathways identified for VIP — Anti-Inflammatory, Bronchodilation, Pulmonary Hypertension — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that reduces collagen deposition in fibrosis models, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, VIP's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
VIP is routinely studied alongside KPV and TA-1 in recovery & healing-focused compound panels. Researchers investigating pulmonary hypertension research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that neuroprotective in models of Parkinson's and ALS has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All VIP research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Phase 2 trials for pulmonary arterial hypertension
- Reduces collagen deposition in fibrosis models
- Neuroprotective in models of Parkinson's and ALS
Ideal For
- Pulmonary hypertension research
- Autoimmune disease studies
- Neuroinflammation research
- COPD/asthma studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on VIP. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Phase 2 trials for pulmonary arterial hypertension
Reduces collagen deposition in fibrosis models
Neuroprotective in models of Parkinson's and ALS
Third-Party Verified Every Batch
Each vial of VIP is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
